BioBlog

Drugmakers breathed a sigh of relief when the courts decided against the HHS rule that television ads would be required to include the price of a 30-day supply of the advertised drug. President Trump indicated he would make a move to help the USA pay similar prices to other nations for drug

In this week’s Innovation Partners BioBlog, we look at several top stories from around the world. New evidence shows that the Affordable Care Act improved cardiac patients’ access thanks to Medicaid expansion. Three states plan to import drugs from Canada where costs for prescription medicines are

The United States Supreme Court has agreed to hear the suit against the government in which insurers claim the government backed out of its agreed corridor payments to offset losses from participation in Obamacare markets by initiating a cap against payments. President Trump has signed an executive

As the presidential election draws ever nearer, the debate over how to address the rising cost of prescription drugs and provide healthcare coverage for all continues to rage. President Trump plans to unveil his healthcare plan soon. Governor Abbott of Texas has signed into law a measure to prevent

This week’s Innovation Partners BioBlog offers unique perspectives on the issues facing the healthcare industry today. Some CEOs, for example, believe that a “Medicare for all” type of health insurance system would improve the economy by decoupling health insurance from the cost of hiring workers.

The annual ASCO Meeting, held in Chicago, May 31-June 4, 2019, explored many issues related to oncology. Exciting developments in the field of early detection include Grail’s liquid biopsy test and data showing that Medicaid expansion helped detect more cases of ovarian cancer earlier, potentially

Senators have been busy in Washington this week crafting drug pricing reform packages and trying to work out a compromise with President Trump and his administration on various bills related to healthcare reform and drug pricing. New research in oncology sees FDA approval for a breakthrough

Although the Centers for Medicare and Medicaid Services gave the nod to CAR T-cell therapy, they’re still balking at paying for the treatment. This week, several articles in the Innovation Partners BioBlog look at how the nation’s health insurance industry, led by Medicare and Medicaid, are out of